Navigation Links
Nventa announces publication of HspE7 data
Date:9/24/2007

- HspE7 Demonstrates Ability to Elicit Long-Lasting Tumor Protection In

Vivo; Lead Candidate May Have Utility in HPV-infected Patients With

Invasive Cancer and/or HIV -

SAN DIEGO, CA, Sept. 24 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced the publication of in vivo results of its lead therapeutic vaccine candidate for the treatment of human papillomavirus (HPV)-related diseases, HspE7, in Clinical and Vaccine Immunology, August 2007. The results reported originate from a study undertaken to characterize the cellular anti-E7 immune response induced by HspE7 and to determine the optimum dosing regimen for inducing effective antitumor immunity.

These published study results demonstrated that a single injection of HspE7 is capable of eliciting long-lasting memory CD8+ T cells and conferring protection against tumor challenges in mice lacking CD4+ functions. CD8+ T cells are a type of white blood cell capable of inducing the death of infected somatic or tumor cells by killing cells infected with viruses (or other pathogens) or otherwise damaged or dysfunctional. These data further demonstrated that two HspE7 immunizations protected a higher proportion of mice for a longer duration.

"These results further strengthen our belief that HspE7 is a promising immunotherapeutic agent for treating HPV-related diseases," said Peter Emtage, Ph.D., Vice President, Research and Development at Nventa. "The ability of HspE7 to induce memory CD8+ T cells in the absence of CD4+ help is significant and suggests that our HspE7 fusion protein may have utility in individuals with compromised CD4+ functions, such as those with invasive cancer and/or human immunodeficiency virus infection."

HPV has been detected in most anogenital cancers, and HPV type 16 (HPV16) is closely associated with severe cervical dysplasia and with cervical, anal and approximately 25 percent of head and neck cancers
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Aethlon Medical, Inc. ... biofiltration devices to treat life-threatening diseases, today announced that ... conference call and webcast on Thursday, August 13, 2015 ... and webcast will follow the release of fiscal 2016 ... will be available approximately two hours after the call ...
(Date:8/3/2015)... -- E-QURE Corp. (OTCQB: EQUR), a Delaware ... Therapy device ("BST Device"), a new and novel electrotherapy ... wounds, today announced that the Company has signed its ... in medical devices, for the marketing and distribution of ... years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... , Aug. 3, 2015   Intrexon Corporation ... release first half and second quarter 2015 financial results ... , 2015.  The Company will host a conference call ... provide a general business update. The conference ... and 1-412-902-4262 (International), and asking to join the "Intrexon ...
(Date:8/3/2015)... According to a new market ... Asia to Witness Highest Growth ... cell culture market was valued at US$ 586.1 Mn in ... of 29.1% to account for US$ 2,717.6 Mn by ... 3D cell culture refers to a ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4
... Corporation (Nasdaq: DNDN ) today announced that management ... in San Francisco on Thursday, January 15, 2009 at 11:00 ... presentation will be accessible through the Investor Relations section of ... to listen to the live webcast, it will be archived ...
... CRANBURY, N.J., Jan. 8 Amicus Therapeutics (Nasdaq: ... J. Barer, Ph.D., to its Board of Directors. ... Officer of Celgene Corporation. As an industry veteran, ... and a reputation as a trusted and respected leader ...
... CAMBRIDGE, Mass. January 7, 2008 Researchers from Harvard ... for the first time, a repulsive quantum mechanical force that ... new nanotechnology applications. , The study, led by Federico Capasso, ... of Engineering and Applied Science (SEAS), will be published as ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Researchers measure elusive repulsive force from quantum fluctuations 2
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Evolution Group participated in an international research that has resulted ... fly species. The study also includes new data on the ... sixty million years. The research, published in Nature, was ... over the world and consisted in the analysis of the ...
... Inc. and the Prostate Cancer Foundation today announced they ... Program (for Special Team Amplification of Research), an innovative ... heat in cancer therapy to treat prostate cancer, as ... is being launched for the first phase of research ...
... (November 15, 2007) -- In response to the need ... populations of the threatened staghorn coral, Diego Lirman, Ph.D., ... Rosenstiel School of Marine and Atmospheric Science (RSMAS) have ... of staghorn corals. The goals of the coral ...
Cached Biology News:Genome comparison of 12 fruit fly species 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 4New south Florida nursery to focus on staghorn corals 2
... the ultimate in utility and flexibility press-to-seal ... the needs of the researcher. They are ... or as sheet material that can be ... isolators are autoclavable and non-cytotoxic and can ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: